Page last updated: 2024-11-04

4-chlorophenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Chlorophenol is a colorless to light yellow solid with a pungent odor. It is used as an intermediate in the synthesis of various pesticides, herbicides, and pharmaceuticals. 4-Chlorophenol is also used as a wood preservative and as a disinfectant. It is toxic to aquatic life and can cause skin and eye irritation. 4-Chlorophenol is a known environmental contaminant, and its presence in water and soil can pose a risk to human health. 4-Chlorophenol is studied because of its potential toxicity and its prevalence in the environment. Research focuses on understanding its environmental fate and transport, its effects on human health, and methods for its remediation.'

4-chlorophenol: used as a root canal irrigant [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-chlorophenol : A monochlorophenol substituted at the pare position by a chlorine atom. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4684
CHEMBL ID57053
CHEBI ID28078
SCHEMBL ID28864
MeSH IDM0093086

Synonyms (129)

Synonym
BIDD:ER0011
nsc2877
phenol, 4-chloro-
p-chlorfenol
phenol, p-chloro-
nsc-2877
4-hydroxychlorobenzene
wln: qr dg
CHEBI:28078 ,
KBIO1_000310
DIVK1C_000310
parachlorophenol (jan/usp)
D00149
SPECTRUM_000939
SPECTRUM5_001228
IDI1_000310
BSPBIO_002157
inchi=1/c6h5clo/c7-5-1-3-6(8)4-2-5/h1-4,8
NCGC00090814-01
parachlorophenol [usp]
ai3-19422
p-chlorophenic acid
einecs 203-402-6
nsc 2877
4-monochlorophenol
ccris 642
hsdb 1414
applied 3-78
4-chloro-1-hydroxybenzene
p-chlorfenol [czech]
parachlorophenol
106-48-9
C02124
4-chlorophenol
p-chlorophenol
4-chlorophenol, >=99%
NCGC00090814-03
NCGC00090814-02
KBIO3_001657
KBIO2_006555
KBIOGR_000916
KBIO2_001419
KBIOSS_001419
KBIO2_003987
SPECTRUM3_000539
SPECTRUM4_000468
SPECTRUM2_000968
SPBIO_000975
NINDS_000310
SPECTRUM1500460
NCGC00090814-04
MLS002454432
smr001252242
HMS2091N08
4ch ,
CHEMBL57053
p-chlorophenol, liquid [un2021] [keep away from food]
BMSE000461
p-chlorophenol, solid [un2020] [keep away from food]
HMS500P12
HMS1920F08
AKOS000118967
NCGC00090814-05
dtxcid201871
cas-106-48-9
tox21_302860
NCGC00256497-01
dtxsid1021871 ,
tox21_201704
NCGC00259253-01
4-chloro-phenol
4-chlorphenol
nsc757263
pharmakon1600-01500460
nsc-757263
tox21_111028
HMS2230B13
CCG-40184
3dlc36a01x ,
p-chlorophenol, liquid
unii-3dlc36a01x
ec 203-402-6
p-chlorophenol, solid
FT-0618238
parachlorophenol [usp monograph]
parachlorophenol [mart.]
4-chlorphenol [who-dd]
parachlorophenol [vandf]
parachlorophenol [usp-rs]
p-chlorophenol [mi]
parachlorophenol [hsdb]
p-chlorophenol [inci]
parachlorophenol [jan]
HMS3373O02
bdbm36299
SCHEMBL28864
NCGC00090814-07
tox21_111028_1
4-clc6h4oh
para-chlorophenol
4chlorophenol
parachloro phenol
4-chloro phenol
4-chlorophenol-2,3,5,6-d4,od
344298-84-6
AB00052066_06
mfcd00002318
J-001599
F0001-0124
SR-05000001691-1
sr-05000001691
4-chlorophenol, puriss., >=99.0% (gc)
parachlorophenol, united states pharmacopeia (usp) reference standard
4-chlorophenol, pestanal(r), analytical standard
4-chlorophenol, for synthesis, 98%
4-chlorophenol 10 microg/ml in methanol
4-chlorophenol 100 microg/ml in methanol
SBI-0051474.P003
DB13154
CS-0005709
p-chloro-phenol
2,4-d tp3
parachlorophenol,(s)
Q2179668
BRD-K40992116-001-05-5
EN300-19291
STL194293
4-(chlorophenyl) -2 3 5 6-d4 98 atom %d
Z104473434

Research Excerpts

Toxicity

The toxic effects of photoproducts formed upon the photolysis of 2- and 4-chlorophenol (CP) frozen solutions in polycrystalline ice phase were determined with a bacterial luminescence test (Vibrio fisheri) and in vitro biomarker assay for dioxin-like effects. Intermediates products were all less toxic than 4- chlorophenol.

ExcerptReferenceRelevance
"Chlorophenols, mainly used as biocides, are compounds with a wide spectrum of toxic effects, including teratogenic and carcinogenic actions."( Involvement of oxidative sress in the toxicity of 4-monochlorophenol in Hep G2 cells in culture.
Colein, P; Garçon, G; Grave-Descampiaux, B; Hannothiaux, MH; Shirali, P; Truffin, D,
)
0.13
"The toxic effects of photoproducts formed upon the photolysis of 2- and 4-chlorophenol (CP) frozen solutions in polycrystalline ice phase were determined with a bacterial luminescence test (Vibrio fisheri), and in vitro biomarker assay for dioxin-like effects (inductions of AhR-dependent luciferase in H4IIE-luc cells) and compared to the toxic effects of products of the same photoreaction in aquatic phase."( Toxicity increases in ice containing monochlorophenols upon photolysis: environmental consequences.
Bláha, L; Janosek, J; Klán, P; Klánová, J; Růzicka, R; Skarek, M, 2004
)
0.56
"Chlorinated phenolic compounds present in some chemical industry wastewaters cause severe toxic effects on the organisms and often are resistant to biological degradation."( COD, para-chlorophenol and toxicity removal from para-chlorophenol containing synthetic wastewater in an activated sludge unit.
Kargi, F; Konya, I, 2006
)
0.33
" The transpiration of the trees was used to determine toxic effects."( Uptake, removal, accumulation, and phytotoxicity of 4-chlorophenol in willow trees.
Trapp, S; Ucisik, AS, 2008
)
0.6
" High feed 4-CP contents adversely affected the system performance due to toxic effects of 4-CP on microorganisms."( COD, para-chlorophenol and toxicity removal from synthetic wastewater using rotating tubes biofilm reactor (RTBR).
Eker, S; Kargi, F, 2010
)
0.36
" Intermediates products were all less toxic than 4-chlorophenol and a significant removal of the overall toxicity was accomplished."( Photocatalytic degradation of 4-chlorophenol under P-modified TiO2/UV system: kinetics, intermediates, phytotoxicity and acute toxicity.
Elghniji, K; Hentati, O; Ksibi, M; Mahfoudh, A; Mlaik, N, 2012
)
0.92
" The non-chemical technologies showed advantages in terms of complete (in the case of adsorption) or easy (enzymatic treatments) removal of toxic treatment by-products."( Removal efficiency and toxicity reduction of 4-chlorophenol with physical, chemical and biochemical methods.
Christofi, N; Dams, R; Gómez, E; Gómez, JL; Gómez, M; Murcia, MD,
)
0.39
" In addition, antioxidant activity of CNCP was evaluated and its safe dose was identified."( In vivo acute toxicity and anti-gastric evaluation of a novel dichloro Schiff base: Bax and HSP70 alteration.
Hussaini, J; Khalilzadeh, M; Majid, NA; Rad, SK; Saremi, K, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of pollutants, pesticides and/or their degradation products in soil depends on the strength of their sorption by the different soil components, particularly by the clay minerals."( Sorption and desorption behavior of chloroanilines and chlorophenols on montmorillonite and kaolinite.
Gennaro, MC; Gianotti, V; Gosetti, F; Polati, S, 2006
)
0.33
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"2 mmol/kg body wt, twice a day) produced significant elevations in fasting serum glucose levels, but this dosage of 4-CP did not alter serum lipid and lipoprotein parameters, whereas clofibrate significantly reduced serum total cholesterol and high density lipoprotein cholesterol levels."( Pharmacologic effects of 4-chlorophenol in rats: comparison to clofibrate.
Feller, DR; Hanson, JM; Newman, HA; Patel, ST; Phornchirasilp, S; Witiak, DT, 1989
)
0.58
" A dose-response relationship was observed for both fibroblasts and bacteria."( A comparison of the antibacterial and cytotoxic effects of parachlorophenol.
Feigal, RJ; Messer, HH, 1985
)
0.27
" The maximum toxicity normally occurred before the maximum color intensity was monitored, while ozone dosage applied was within 1 mg of ozone per mg of initial CPs."( Variation of toxicity during the ozonation of monochlorophenolic solutions.
Ma, HW; Shang, NC; Yu, YH, 2002
)
0.31
" The influence of initial concentration and adsorbent dosage was studied."( Sorption of phenol and 4-chlorophenol onto pumice treated with cationic surfactant.
Akbal, F, 2005
)
0.64
" The influence of some operating conditions such as temperature, dosage of hydrogen peroxide and initial concentration of the chlorophenols was studied in absence of a catalyst."( Wet peroxide oxidation of chlorophenols.
Chamarro, E; Esplugas, S; Florczyk, M; García-Molina, V; López-Arias, M, 2005
)
0.33
" Several factors affecting the degradation of 4CP by MW/UV/TiO2 method, such as the dosage of photocatalysts, the initial pH value of the solutions, gas bubbling, light intensity and addition of H2O2 oxidant, were studied in detail."( Degradation of 4-chlorophenol by a microwave assisted photocatalysis method.
Ai, Z; Lu, X; Yang, P, 2005
)
0.68
"This paper presents a simple, specific, and precise high-performance liquid chromatographic method for the simultaneous determination of paracetamol (PCM), chlorzoxazone (CXZ), and their related impurities in bulk raw materials and solid dosage forms."( Simultaneous determination of paracetamol, chlorzoxazone, and related impurities 4-aminophenol, 4'-chloroacetanilide, and p-chlorophenol in pharmaceutical preparations by high-performance liquid chromatography.
Ali, MS; Ghori, M; Kahtri, AR; Rafiuddin, S,
)
0.13
" Differences in granules shape and size were observed with 4CP and TCP dosed in the influent, and the effects of such toxic compounds on acetate removal were evaluated."( Acetate-fed aerobic granular sludge for the degradation of chlorinated phenols.
Carucci, A; De Gioannis, G; Milia, S; Piredda, M, 2008
)
0.35
" Differences in granules shape and size were observed with 4CP dosed in the influent at different concentrations, and the effects of such toxic compound on acetate removal were evaluated, with both unacclimated and acclimated biomass."( Acetate-fed aerobic granular sludge for the degradation of 4-chlorophenol.
Carucci, A; De Gioannis, G; Milia, S; Piredda, M, 2009
)
0.6
" A conventional Sequencing Batch Reactor (SBR) and a Membrane BioReactor (MBR) were operated in parallel under the same 4CP influent concentrations and/or 4CP volumetric organic loading rates as the GSBR, in order to carry out a direct comparison in terms of 4CP removal efficiencies and specific removal rates, effluent quality, waste sludge production, system simplicity, land area requirement, start-up times, NaAc dosage as growth substrate and maximum applied 4CP volumetric organic loading rate."( A direct comparison amongst different technologies (aerobic granular sludge, SBR and MBR) for the treatment of wastewater contaminated by 4-chlorophenol.
Cappai, G; Carucci, A; Milia, S; Muntoni, A, 2010
)
0.56
" The effects of different 4CP/NaAc ratios on SBR performances were evaluated in terms of 4CP removal efficiencies and maximum specific removal rates in order to maximize reactor performances: a decrease in NaAc dosage as external growth substrate would lead to definitely lower operating costs."( Effects of the cometabolite/growth substrate ratio on the aerobic degradation of 4-monochlorophenol.
Cappai, G; Carucci, A; De Gioannis, G; Milia, S, 2011
)
0.37
" In contrast, for H2O2 dosing (proportional continuous or cumulative one-time), the flow rate did not significantly affect process efficacy."( A highly effective photochemical system for complex treatment of heavily contaminated wastewaters.
Hejda, S; Kluson, P; Krystynik, P; Masin, P; Tito, DN, 2014
)
0.4
" The critical effect of ox dosing was confirmed with the reactive species of [Fe(II)(ox)0] and [Fe(II)(ox)2 (2-)]."( Oxalate-assisted oxidative degradation of 4-chlorophenol in a bimetallic, zero-valent iron-aluminum/air/water system.
Fan, J; Ma, L; Wang, H, 2016
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monochlorophenol
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
chlorinated phenols degradation110

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency19.20680.000714.592883.7951AID1259369; AID1259392
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency9.52050.000214.376460.0339AID720691
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency60.19930.001530.607315,848.9004AID1224848; AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency60.71080.000229.305416,493.5996AID743069
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency18.83360.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency53.08040.000627.21521,122.0200AID651741
gemininHomo sapiens (human)Potency0.19950.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Oxysterols receptor LXR-betaHomo sapiens (human)Ki169.00000.00220.07300.3520AID1562690
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Oxysterols receptor LXR-betaHomo sapiens (human)EC50 (µMol)514.00000.00010.40077.3000AID1562693
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
hormone-mediated signaling pathwayOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of triglyceride biosynthetic processOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of cholesterol effluxOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of lipid storageOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of cholesterol storageOxysterols receptor LXR-betaHomo sapiens (human)
intracellular receptor signaling pathwayOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of lipid transportOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of cholesterol transportOxysterols receptor LXR-betaHomo sapiens (human)
phosphatidylcholine acyl-chain remodelingOxysterols receptor LXR-betaHomo sapiens (human)
cholesterol homeostasisOxysterols receptor LXR-betaHomo sapiens (human)
mRNA transcription by RNA polymerase IIOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of fatty acid biosynthetic processOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of proteolysisOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of DNA-templated transcriptionOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of pinocytosisOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of lipoprotein lipase activityOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of protein metabolic processOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of high-density lipoprotein particle assemblyOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of pancreatic juice secretionOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of secretion of lysosomal enzymesOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of cold-induced thermogenesisOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of miRNA transcriptionOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressOxysterols receptor LXR-betaHomo sapiens (human)
cell differentiationOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIOxysterols receptor LXR-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingOxysterols receptor LXR-betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificOxysterols receptor LXR-betaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificOxysterols receptor LXR-betaHomo sapiens (human)
DNA bindingOxysterols receptor LXR-betaHomo sapiens (human)
protein bindingOxysterols receptor LXR-betaHomo sapiens (human)
zinc ion bindingOxysterols receptor LXR-betaHomo sapiens (human)
chromatin DNA bindingOxysterols receptor LXR-betaHomo sapiens (human)
apolipoprotein A-I receptor bindingOxysterols receptor LXR-betaHomo sapiens (human)
nuclear retinoid X receptor bindingOxysterols receptor LXR-betaHomo sapiens (human)
ATPase bindingOxysterols receptor LXR-betaHomo sapiens (human)
nuclear receptor activityOxysterols receptor LXR-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleusOxysterols receptor LXR-betaHomo sapiens (human)
nucleoplasmOxysterols receptor LXR-betaHomo sapiens (human)
cytoplasmOxysterols receptor LXR-betaHomo sapiens (human)
cytosolOxysterols receptor LXR-betaHomo sapiens (human)
RNA polymerase II transcription regulator complexOxysterols receptor LXR-betaHomo sapiens (human)
chromatinOxysterols receptor LXR-betaHomo sapiens (human)
nucleusOxysterols receptor LXR-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (103)

Assay IDTitleYearJournalArticle
AID310932Permeability across human Skin2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1133175Molar volume, Vm of the compound at zero temperature1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Molar volume relationships and the specific inhibition of a synaptosomal enzyme by psychoactive cannabinoids.
AID266765Effective permeability coefficient in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID40623Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined.1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID282838Cytotoxicity against human CCRF-CEM cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID1562694Agonist activity at recombinant human LXRbeta-LBD expressed in human HEK293T cells incubated for 20 hrs by luciferase reporter gene assay relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay.
AID266763Membrane retention in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID282835Cytotoxicity against mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID203473Binding constant against bovine serum albumin1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID266771Permeability in human skin2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1608996Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1608994Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1608992Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1292259Cytotoxicity against human MCF7cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID1133174Antihemolytic potency against hypotonic lysis-induced erythrocytes (unknown origin) assessed as stabilization1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Molar volume relationships and the specific inhibition of a synaptosomal enzyme by psychoactive cannabinoids.
AID23714Partition coefficient (logP)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID1562693Agonist activity at recombinant human LXRbeta-LBD expressed in Escherichia coli BL21 (DE3) assessed as peptide D22 recruitment fluorescence polarization binding assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay.
AID1608997Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1608999Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1134603Oleyl alcohol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID1133173Inhibition of mouse brain synaptosomal Lysophosphatidylcholine acyltransferase using substrate [32P]lysophosphatidylcholine and oleoyl-CoA1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Molar volume relationships and the specific inhibition of a synaptosomal enzyme by psychoactive cannabinoids.
AID282839Cytotoxicity against human CEM/VLB cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID26793Partition coefficient (logP)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID26261Partition coefficient (logD7.2)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1292257Cytotoxicity against human HeLa cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID1292258Cytotoxicity against human KB cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID1134600Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID1145386Partition coefficient, log P of the compound by shake-flask technique1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.
AID23978Capacity ratio (log k'w)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID1292260Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID1608991Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID385221Lipophilicity, log P of the compound2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
Synthesis and screening of mono- and di-aryl technetium and rhenium metallocarboranes. A new class of probes for the estrogen receptor.
AID1145387Partition coefficient, log P of the compound by HPLC analysis1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1562692Competitive binding affinity to recombinant human LXRbeta-LBD expressed in Escherichia coli BL21 (DE3) at 1 mM incubated for 30 mins by fluorescence polarization binding assay relative to tracer 12019European journal of medicinal chemistry, Sep-15, Volume: 178Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay.
AID1608995Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID266764Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1149269Antimicrobial activity against Aspergillus niger1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Quantitative structure-activity relationships. 2. A mixed approach, based on Hansch and Free-Wilson Analysis.
AID266766Dissociation constant, pKa of the compound2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1268193Drug level in HEPES buffer treated with 200 uM (S)-4-chlorophenyl 3-(2-amino-4-methylpentanamido)propane-1-sulfonate in presence of aeromonas proteolytica aminopeptidase by spectrophotometry2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Development of a novel sulfonate ester-based prodrug strategy.
AID40936Inhibition of Bacillus subtilis PCI219 spore germination, expressed as log 1/I501982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1608990Antimycobacterial activity against Mycobacterium avium 330/88 after 14 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1562690Binding affinity to recombinant human LXRbeta-LBD expressed in Escherichia coli BL21 (DE3) assessed as inhibitory constant incubated for 30 mins by fluorescence polarization binding assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay.
AID1608993Antimycobacterial activity against Mycobacterium avium 330/88 after 21 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1292261Cytotoxicity against HDF cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID25611Dissociation constant (pKa)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1608998Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID282833Activity against caspase-mediated apoptosis in mouse L1210 cells at 0.1 mM2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID19211Calculated partition coefficient (clogP)2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Utility of boron clusters for drug design. Hansch-fujita hydrophobic parameters pi of dicarba-closo-dodecaboranyl groups.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (540)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (5.56)18.7374
1990's43 (7.96)18.2507
2000's205 (37.96)29.6817
2010's214 (39.63)24.3611
2020's48 (8.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.79 (24.57)
Research Supply Index6.34 (2.92)
Research Growth Index5.06 (4.65)
Search Engine Demand Index85.84 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (0.53%)6.00%
Case Studies1 (0.18%)4.05%
Observational0 (0.00%)0.25%
Other559 (99.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]